Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Staging systems for multiple myeloma: a comparison.

W Gassmann, H Pralle, T Haferlach

British Journal of Haematology

|April 1, 1985

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chronic Lymphocytic Leukemia (B-CLL) and Immunocytoma (LP-IC): Clinical and Prognostic Relevance of this Distinction.

Leukemia & lymphoma·2016

Same author

Mutations in the sodium channel gene SCN2A cause neonatal epilepsy with late-onset episodic ataxia.

Journal of neurology·2015

Same author

[Trend sports].

Der Unfallchirurg·2015

Same author

Contact allergy induced by bisphenol A diglycidyl ether leachables from aluminium tubes for pharmaceutical use.

Allergy·2015

Same author

Skin irritability to sodium lauryl sulfate is associated with increased positive patch test reactions.

The British journal of dermatology·2014

Same author

[Cancer of unknown primary. Epidemiology and pathogenesis].

Der Radiologe·2014

Same journal

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol.

British journal of haematology·2026

Same journal

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

British journal of haematology·2026

Same journal

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026

Same journal

Novel germline GATA1s-generating variant associates with somatic STAG2 variants in hypoplastic myelodysplastic neoplasm.

British journal of haematology·2026

Same journal

The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.

British journal of haematology·2026

Same journal

Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.

British journal of haematology·2026

See all related articles

Evaluating seven multiple myeloma staging systems in 152 patients, the British Medical Research Council (1980) system showed the most significant survival differences. However, no system surpassed individual factors like creatinine and hemoglobin for prognosis.

Area of Science:

Hematology
Oncology
Clinical Research

Background:

Multiple myeloma prognosis relies on accurate staging systems.
Previous systems showed varying prognostic capabilities.

Purpose of the Study:

To evaluate the prognostic value of seven established multiple myeloma staging systems.
To identify the most effective staging system for patients treated with cytostatic agents.

Main Methods:

Retrospective analysis of 152 multiple myeloma patients treated with cytostatic agents.
Comparison of survival data across seven distinct staging systems: Carbone et al (1967), ALGB/ECOG (1973), SECSG (1975), Durie & Salmon (1975), Alexanian et al (1975), Merlini et al (1980), and British Medical Research Council (1980).

Main Results:

Related Experiment Videos

The British Medical Research Council (1980) system demonstrated significant survival differences across its three stages (A, B, C) with median survival times of 83, 52, and 26 months, respectively.
Other systems like ALGB and SECSG showed significant differences but with smaller survival gaps.
Systems by Carbone et al, Merlini et al, Alexanian et al, and Durie & Salmon had mixed statistical significance in survival differences.
No staging system proved superior to individual prognostic factors such as creatinine and hemoglobin levels.

Conclusions:

The British Medical Research Council (1980) staging system offers the most distinct prognostic stratification for multiple myeloma patients.
Despite statistical significance, individual risk factors like creatinine and hemoglobin remain highly valuable prognostic indicators, potentially outperforming complex staging systems.